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Impact of the MTHFR C677T polymorphism on risk of neural tube
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Mary Conley, Philip D Mayne, Owen Smith, John M Scott
Homozygosity for the T allele of the C677T polymorphism of
the gene encoding the folate dependent enzyme 5,10-
methylenetetrahydrofolate reductase (MTHFR) is a risk factor
for neural tube defects.1 Both the homozygous (TT) and hetero-
zygous (CT) genotypes are associated with lower tissue
concentrations of folate, higher homocysteine concentrations,
and lower enzyme activity than the wild type (CC) genotype;
these effects are more marked in homozygotes. Low folate and
raised homocysteine levels in early pregnancy are risk factors for
neural tube defects.2 We investigated the possibility that the CT
genotype would also increase the risk of these malformations.
Participants, methods, and results
We recruited 397 individuals with spina bifida aperta (380) or
encephalocele (17) throughout Ireland. Participants were aged
between 5 months and 52 years (mean 16.8 years). We drew
blood for analysis of DNA. We derived the controls from a
random sample of 1000 newborn screening cards collected on
all Irish births. Of these 1000, DNA was successfully extracted
from 855 cards. We successfully genotyped 395 (99.5%) cases
and 848 (99.2%) controls.
We calculated population attributable fractions, broadly
interpreted as the percentage of the disease in a population that
is “caused by” a risk factor, for heterozygotes and homozygotes
separately comparing each to the wild type.
The heterozygous genotype is associated with an increased
risk of neural tube defects (odds ratio 1.52; P = 0.0015; table).
Risk is also raised for the homozygous TT genotype (2.56;
P < 0.0001) confirming our earlier finding.3
Population attributable fraction calculations reveal that the
CT genotype is responsible for at least as many neural tube
defects in the population as the TT genotype (14.9% v 11.3%;
table). This arises because a much greater proportion of the
population are heterozygous for this allele (about 38% of the
general population are CT compared with 10% who are TT;
table).
Comment
Heterozygosity for the MTHFR polymorphism, which is present
in 38% of the population, increases the risk of neural tube
defects. Most studies of MTHFR C677T and neural tube defects
and other conditions, have focused on the risk associated with T
allele homozygosity. The possibility that heterozygosity might
also increase neural tube defect risk has gone unrecognised
except for a small study in which an association between CT and
these malformations was thought to be due to the higher than
expected proportion of CC control subjects.4
The combined CT and TT genotypes account for about 26%
of neural tube defects in Ireland. Folate or folic acid is estimated
to be involved in about 50% to 70% of these defects. Thus up to
a half of the folate related neural tube defects may be explained
by this single genetic variant.
These findings have two important implications. Firstly,
MTHFR C677T heterozygosity needs to be considered as a risk
factor for other conditions where homozygosity has been shown
to be associated with increased risk, for example, ischaemic heart
disease.5 Secondly, the population at risk, and the population that
will benefit from food fortification, is much larger than
previously believed. Based on pooled data from published stud-
ies, about 59% of the European population and 53% of the
North American population have either CT or TT genotypes.1
Both the lower folate and increased homocysteine concen-
trations associated with CT and TT genotypes can be corrected
by folic acid, even in relatively small doses. Therefore, our study
provides new data underscoring the importance of public health
intervention programmes of folic acid supplementation and
food fortification targeted at all women of childbearing age to
prevent neural tube defects. Such intervention may also turn out
to have other public health benefits—for example, in the preven-
tion of cardiovascular disease.
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Risk of neural tube defect by the 5,10-methylenetetrahydrofolate reductase C677T genotype
Genotype No of cases (%) No of controls (%) Odds ratio (95% CI) P value
Population attributable fraction%
(95% CI)
CC (wild type) 151 (38.2) 439 (51.8) 1.00 — —
CT (heterozygous) 171 (43.3) 326 (38.4) 1.52 (1.16 to 2.00) 0.0015 14.9 (6.1 to 23.7)
TT (homozygous) 73 (18.5) 83 (9.8) 2.56 (1.75 to 3.74) <0.0001 11.3 (6.7 to 15.8)
CT or TT 244 (61.8) 409 (48.2) 1.73 (1.40 to 2.14) <0.0001 26.2 (15.7 to 36.6)
Total 395 (100) 848 (100) — — —
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